

COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	1,300,000,000
Gender F/M (%):	48.5 / 51.5
Population, age group <15/ ≥15 years (%):	29 / 71
Life expectancy at birth (F/M, years) (2015):	70 / 67
GDP (PPP int \$):	6,050
Income status:	Lower middle
Number of 3 rd sub-national administrative level divisions, name:	6612*, Block

* https://data.gov.in/catalog/number-districts-drdas-blocks-villages-country#web_catalog_tabs_block_10

EPIDEMIOLOGY


	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	8,500	No data	648	N/A
Number of relapse ¹ cases:	No data	No data	N/A	N/A
Total number of cases:	8,500	No data	648	N/A
Imported cases (#, %):	0, 0%	No data	N/A	N/A
Gender distribution (% F):	39	No data	N/A	N/A
Age group distribution (% < 5/5-14/>14):	(4/27/53)	No data	(1/20/76)	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.62	No data	N/A	N/A
Number of endemic 3 rd sub-national administrative level divisions:	603	No data	N/A	N/A
Population at risk ² (% # at risk/total population):	10% 136,482,825/1,300,000,000	No data	N/A	N/A
Was there any outbreak?	Yes	Unknown	N/A	N/A
Number of new ³ foci:	No data	No data	N/A	N/A

N/A = Not applicable; ¹ Relapse in this country is defined for VL as: "VL: Reappearance of signs and symptoms in a treated patient confirmed by parasite demonstration"; ² Defined as "Number of people living in 3rd sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever".



Monthly distribution of new cases (January-December)

2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	496	806	861	887	827	806	754	633	902	519	417	554
CL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data


VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015



Disease distribution of new VL cases at block level per 10,000 population (2015)



The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1992
Type of surveillance:	Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	DDT, Synthetic Pyrethroids
Year latest national guidelines:	2015
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities:	611

DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides*(% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	No data	No data	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions*(% , # CL cases/ total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection*:	1% (45/8,500)	N/A	0% (0/648)	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus.

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Liposomal Amphotericin B, Sodium stibogluconate (SSG), Amphotericin B deoxycholate, Miltefosine**

TREATMENT OUTCOME

	VL	CL
Proportion of cases treated*(% , # treated cases/ total cases):	94% (7,967/8,500)	No data
Initial cure rate*(% , # cases initially cured /total cases):	No data	No data
Failure rate ⁴ (% , # patients with treatment failure /total cases):	No data	No data
Case fatality rate*(% , # patients who died/ total cases):	0.06% (5/8,500)	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴ Failure in this country is defined as: No definition available.

* These indicators only apply to new cases.